Researchers conducted a post hoc analysis of the EMPA-REG OUTCOME trial involving 5,973 type 2 patients with diabetes patients and with or without left ventricular hypertrophy and found that those who received 10 mg or 25 mg daily of empagliflozin had a reduced risk for all-cause mortality and cardiovascular death and fewer three-point major adverse CV events than those on placebo. The findings were published in Diabetes Care.
Study finds empagliflozin improves CV outcomes in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.